FDA Clearance Tracker · P230036-S017
Esprit BTK Everolimus Eluting Resorbable Scaffold System
Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jul 9, 2026
Approved
Time to decision
99 days
Received Apr 1, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P230036-S017
- Device name
- Esprit BTK Everolimus Eluting Resorbable Scaffold System
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Santa Clara, CA
- Received
- Apr 1, 2026
- Decided
- Jul 9, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P230036
Device type
- Device type
- Scaffold, infrapopliteal, absorbable (NXW)
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
approval for the addition of a Long Length (LL) scaffold version
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.